Can a cancer drug stop a blood disorder before it turns deadly?

NCT ID NCT06802146

Recruiting now Disease control Sponsor: Lachelle D. Weeks, MD, PhD Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This pilot study is for people with high-risk CCUS, a blood condition that can lead to cancer. Participants can choose to be watched or take an oral drug called Inqovi (decitabine/cedazuridine). The goal is to see if early treatment is feasible and safe. The study is small and early, so it won't prove whether the drug works, but it may guide future research.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Decitabine and cedazuridine (Inqovi)
What this could lead to: If successful, this could show that early treatment of high-risk CCUS is feasible and safe, potentially preventing progression to blood cancer.
What could go wrong: This is a very early, small pilot study (108 participants) focused on feasibility and safety, not effectiveness. The drug may cause side effects, and it's unknown if early treatment truly prevents cancer.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CLONAL CYTOPENIA OF UNDETERMINED SIGNIFICANCE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Cytopenia pancytopenia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CLONAL CYTOPENIA OF UNDETERMINED SIGNIFICANCE CYTOPENIA

Contacts and locations

Locations

Dana-Farber Cancer Institute
RECRUITING

Boston, Massachusetts, 02215, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.